Skip to content

News Category: Health & Medical

DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS

By asianet

–  Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. –  Debiopharm is developing Debio 4126, a novel 3-month extended-release octreotide formulation, to optimize acromegaly and GEP-NET patient care by reducing injection frequency, which translates into … Continued

Mars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care

By asianet

– The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care – Insights from this partnership will feed into the MARS PETCARE BIOBANK(TM), a longitudinal study to understand pet health and disease, transforming pet care for future generations of dogs and cats – Mars Petcare Science & Diagnostics President, … Continued

MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval

By asianet

SELUTION SLR(TM), MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions. This comes less than eight months after the company received its first IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications; as well … Continued

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

By asianet

Ajinomoto Co., Inc. (“Ajinomoto Co.”) today announced a license agreement with Exelixis, Inc. (“Exelixis”) to incorporate AJICAP(R), Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis’ antibody-drug conjugate (ADC) programs. Logo – https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and … Continued

Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients

By asianet

Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, is pleased to announce opening of the Investigational New Drug (IND) application with the U.S Food and Drug Administration (FDA) for naronapride for the treatment of GI motility disorders in patients with … Continued

Sai Life Sciences inks strategic agreement to set up Schrödinger’s first dedicated offshore Research Laboratories in India

By asianet

Sai Life Sciences, one of India’s fastest growing global Contract Research, Development & Manufacturing Organisations [ https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=schrodinger-offshore-research-lab ] (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, … Continued

CES 2023: OMRON Healthcare to Unveil New Efforts to Realize Vision of “Going for Zero” — Zero Heart Attacks and Zero Strokes

By asianet

– “Viso,” New UK Remote Patient Monitoring Service, to Be Launching in Early 2023 – OMRON Healthcare Co., Ltd. (hereinafter the Company) is unveiling a new UK remote patient-monitoring service to realize its “Going for Zero” vision to eliminate heart attack and stroke at the world’s largest Consumer Electronic Show (CES 2023). The Company is … Continued

B dot Medical to Install Its First Practical Ultra-compact Proton Therapy System at Hospital in Tokyo

By asianet

– Memorandum of Understanding Signed with Edogawa Hospital – B dot Medical Inc. has signed a memorandum of understanding with Edogawa Hospital in Japan for the installation of the company’s first practical ultra-compact proton therapy system, which means the first proton therapy facility to be established in Tokyo. Logo: https://kyodonewsprwire.jp/img/202212211482-O2-n1O2n8B4 Image1: Edogawa Hospital in Tokyo, … Continued

DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference

By asianet

DiscGenics, Inc. ( https://c212.net/c/link/?t=0&l=en&o=3748183-1&h=827169717&u=https%3A%2F%2Fwww.discgenics.com%2F&a=DiscGenics ), a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA on January … Continued

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment

By asianet

Study met all primary endpoints Alphyn Biologics ( https://c212.net/c/link/?t=0&l=en&o=3747842-1&h=3266796279&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3709054-1%26h%3D2795132862%26u%3Dhttps%253A%252F%252Falphynbiologics.com%252F%26a%3DAlphyn%2BBiologics&a=Alphyn+Biologics ), a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today positive results from the first cohort of its Phase 2a clinical trial of AB-101a, a topical therapeutic for mild-to-moderate atopic dermatitis (AD). The trial met all of its primary endpoints, highlighting AB-101a’s potential to be … Continued